Transcatheter Patent Foramen Ovale Closure in Stroke Patients with Thrombophilia: Current Status and Future Perspectives

키워드

참고문헌 (31)

1. Giacoppo D, "Long-term effectiveness and safety of transcatheter closure of patent foramen ovale compared with antithrombotic therapy alone: a meta-analysis of six randomised clinical trials and 3,560 patients with reconstructed time-to-event data", EuroIntervention, 14, pp.857~867 (2018)
2. Salehi Omran S, "Thrombophilia testing after ischemic stroke: why, when, and what?", Stroke, 52, pp.1874~1884 (2021)
3. Wahed A, "Hematology and Coagulation", pp.265~276 (2020), Academic Press
4. Mac Grory B, "Advances in the management of cardioembolic stroke associated with patent foramen ovale", BMJ, 376, pp.e063161~ (2022)
5. Hviid CV, "Recurrence risk in patients with cryptogenic stroke, patent foramen ovale, and thrombophilia:a systematic review and meta-analysis", Thromb Haemost, 119, pp.1839~1848 (2019)
6. Giardini A, "Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia", Am J Cardiol, 94, pp.1012~1016 (2004)
7. Pristipino C, "European position paper on the management of patients with patent foramen ovale : general approach and left circulation thromboembolism", Eur Heart J, 40, pp.3182~3195 (2019)
8. Messé SR, "Practice advisory update summary : patent foramen ovale and secondary stroke prevention : report of the Guideline Subcommittee of the American Academy of Neurology", Neurology, 94, pp.876~885 (2020)
9. Liu K, "Patent foramen ovale attributable cryptogenic embolism with thrombophilia has higher risk for recurrence and responds to closure", JACC Cardiovasc Interv, 13, pp.2745~2752 (2020)
10. Ben-Assa E, "Efficacy and safety of percutaneous patent foramen ovale closure in patients with a hypercoagulable disorder", Catheter Cardiovasc Interv, 98, pp.800~807 (2021)
11. Buber J, "Patent foramen ovale closure among patients with hypercoagulable states maintained on antithrombotic therapy", Cardiology, 146, pp.375~383 (2021)
12. Kalaria C, "The therapeutic value of laboratory testing for hypercoagulable states in secondary stroke prevention", Neurol Clin, 33, pp.501~513 (2015)
13. Arachchillage DJ, "Thrombophilia testing : a British Society for Haematology guideline", Br J Haematol, 198, pp.443~458 (2022)
14. Lim ST, "Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both", J Neurol Sci, 377, pp.227~233 (2017)
15. Elgendy AY, "Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke", JAMA Neurol, 77, pp.878~886 (2020)
16. Alsheikh-Ali AA, "Patent foramen ovale in cryptogenic stroke : incidental or pathogenic", Stroke, 40, pp.2349~2355 (2009)
17. Pezzini A, "Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale", Stroke, 34, pp.28~33 (2003)
18. Karttunen V, "Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale", Blood Coagul Fibrinolysis, 14, pp.261~268 (2003)
19. Ford MA, "Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack : the Mayo Clinic experience", JACC Cardiovasc Interv, 2, pp.404~411 (2009)
20. Pezzini A, "Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? : systematic review and meta-analysis", Thromb Haemost, 101, pp.813~817 (2009)
21. Debski M, "Contemporary management of patent foramen ovale : a multinational survey on cardiologists’ perspective", J Interv Cardiol, 2021, pp.6955791~ (2021)
22. Omran SS, "Clinical impact of thrombophilia screening in young adults with ischemic stroke", J Stroke Cerebrovasc Dis, 28, pp.882~889 (2019)
23. Offelli P, "Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO)", Thromb Haemost, 98, pp.906~907 (2007)
24. Kefer J, "Percutaneous transcatheter closure of interatrial septal defect in adults : procedural outcome and long-term results", Catheter Cardiovasc Interv, 79, pp.322~330 (2012)
25. Giardini A, "Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale", Int J Cardiol, 120, pp.357~362 (2007)
26. Ding WY, "Relationship between lipoproteins, thrombosis, and atrial fibrillation", Cardiovasc Res, 118, pp.716~731 (2022)
27. Galli M, "Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome : a systematic review of the literature", Blood, 101, pp.1827~1832 (2003)
28. Dodge SM, "Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure", Catheter Cardiovasc Interv, 61, pp.123~127 (2004)
29. Yan C, "Preliminary investigation of in situ thrombus within patent foramen ovale in patients with and without stroke", JAMA, 325, pp.2116~2118 (2021)
30. Botto N, "Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale", Stroke, 38, pp.2070~2073 (2007)
31. Kar S, "Percutaneous closure of patent foramen ovale or atrial septal defect in the presence of thrombophilia", J Struct Heart Dis, 3, pp.135~140 (2017)

관련 논문AI추천